Reading Cancer: Chromatin Readers as Druggable Targets for Cancer Treatment.
chromatin readers
druggable epigenome
small molecule inhibitors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Jan 2019
09 Jan 2019
Historique:
received:
13
12
2018
revised:
30
12
2018
accepted:
03
01
2019
entrez:
13
1
2019
pubmed:
13
1
2019
medline:
13
1
2019
Statut:
epublish
Résumé
The epigenetic machinery deputed to control histone post-translational modifications is frequently dysregulated in cancer cells. With epigenetics being naturally reversible, it represents a good target for therapies directed to restore normal gene expression. Since the discovery of Bromodomain and Extra Terminal (BET) inhibitors, a great effort has been spent investigating the effects of chromatin readers' inhibition, specifically the class of proteins assigned to bind acetylated and methylated residues. So far, focused studies have been produced on epigenetic regulation, dissecting a specific class of epigenetic-related proteins or investigating epigenetic therapy in a specific tumor type. In this review, recent steps toward drug discovery on the different classes of chromatin readers have been outlined, highlighting the pros and cons of current therapeutic approaches.
Identifiants
pubmed: 30634442
pii: cancers11010061
doi: 10.3390/cancers11010061
pmc: PMC6356452
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Italian Minister of Foreigner Affairs and International Cooperation (MAECI)
ID : PGR00223
Références
Oncologist. 2005 Mar;10(3):176-82
pubmed: 15793220
Oncologist. 2007 Oct;12(10):1247-52
pubmed: 17962618
Nat Struct Mol Biol. 2007 Nov;14(11):1025-1040
pubmed: 17984965
Hum Mol Genet. 2008 Oct 1;17(19):3055-74
pubmed: 18632687
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
Biotechnol J. 2011 Sep;6(9):1130-46
pubmed: 21744502
Expert Rev Mol Med. 2011 Sep 13;13:e29
pubmed: 21933453
Int J Cancer. 2012 Nov 1;131(9):2197-203
pubmed: 22322883
Nat Med. 2012 Mar 11;18(4):605-11
pubmed: 22406747
Biochem Soc Trans. 2012 Apr;40(2):364-9
pubmed: 22435813
Cell. 2012 Mar 30;149(1):214-31
pubmed: 22464331
Cell Cycle. 2012 Apr 15;11(8):1634-45
pubmed: 22487681
N Engl J Med. 2012 Aug 16;367(7):647-57
pubmed: 22894577
Expert Opin Ther Targets. 2013 Feb;17(2):179-93
pubmed: 23234477
Nat Chem Biol. 2013 Mar;9(3):184-91
pubmed: 23292653
Brief Funct Genomics. 2013 May;12(3):205-18
pubmed: 23401080
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
Epigenetics Chromatin. 2013 Jul 05;6(1):20
pubmed: 23826629
Cancer J. 2013 Jul-Aug;19(4):324-32
pubmed: 23867514
PLoS One. 2013 Dec 11;8(12):e83018
pubmed: 24349422
ChemMedChem. 2014 Mar;9(3):466-83
pubmed: 24449612
Cancer Discov. 2014 May;4(5):564-77
pubmed: 24535671
Biochim Biophys Acta. 2014 Aug;1839(8):711-8
pubmed: 24747175
Mol Cell Endocrinol. 2014 Jul 5;392(1-2):8-13
pubmed: 24813658
Biomaterials. 2014 Aug;35(25):7101-9
pubmed: 24836306
Sci Rep. 2014 May 29;4:5105
pubmed: 24870050
Br J Pharmacol. 2015 Jun;172(11):2716-32
pubmed: 25039449
Chem Rev. 2015 Mar 25;115(6):2274-95
pubmed: 25424540
Neurotox Res. 2015 Feb;27(2):172-97
pubmed: 25516120
Expert Opin Drug Deliv. 2015;12(9):1501-12
pubmed: 25739728
Biomaterials. 2015 May;51:208-215
pubmed: 25771011
Am J Transl Res. 2015 Mar 15;7(3):616-23
pubmed: 26045900
EMBO Rep. 2015 Nov;16(11):1467-81
pubmed: 26474904
Mol Oncol. 2016 Feb;10(2):292-302
pubmed: 26588862
Biochem Pharmacol. 2016 Apr 15;106:1-18
pubmed: 26707800
Endocr Relat Cancer. 2016 Apr;23(4):335-47
pubmed: 26911376
Cold Spring Harb Perspect Biol. 2016 Apr 01;8(4):a019521
pubmed: 27037415
Oncotarget. 2016 Jun 21;7(25):37740-37754
pubmed: 27192115
Oncotarget. 2016 Aug 16;7(33):53997-54009
pubmed: 27283767
Cell Rep. 2016 Jun 28;16(1):133-147
pubmed: 27320920
PLoS One. 2016 Jul 12;11(7):e0159180
pubmed: 27403962
Front Genet. 2016 Jun 28;7:122
pubmed: 27446204
Onco Targets Ther. 2016 Sep 28;9:5943-5953
pubmed: 27729803
Drug Discov Today Technol. 2016 Mar;19:57-63
pubmed: 27769359
Drug Discov Today Technol. 2016 Mar;19:65-71
pubmed: 27769360
Epigenomics. 2016 Dec;8(12):1637-1651
pubmed: 27882781
J Med Chem. 2017 Jan 26;60(2):668-680
pubmed: 28068087
Expert Opin Drug Discov. 2017 May;12(5):449-463
pubmed: 28277835
J Mol Biol. 2017 Jun 30;429(13):1994-2002
pubmed: 28300602
Science. 2017 Mar 17;355(6330):1147-1152
pubmed: 28302822
Gynecol Oncol Rep. 2017 Mar 21;20:81-86
pubmed: 28378010
Cancer Treat Rev. 2017 Apr;55:200-208
pubmed: 28431263
Mol Cell Endocrinol. 2018 Jul 5;469:38-47
pubmed: 28579118
J Mol Med (Berl). 2017 Aug;95(8):799-807
pubmed: 28681078
Curr Opin Chem Biol. 2017 Aug;39:116-125
pubmed: 28689146
Sci Transl Med. 2017 Jul 26;9(400):
pubmed: 28747513
Genes (Basel). 2017 Aug 07;8(8):null
pubmed: 28783137
Ann Oncol. 2017 Aug 1;28(8):1776-1787
pubmed: 28838216
Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143
pubmed: 28918016
Genes Dis. 2017 Jun;4(2):43-63
pubmed: 28944281
Front Oncol. 2017 Oct 12;7:241
pubmed: 29075615
Sci Rep. 2017 Dec 7;7(1):17113
pubmed: 29215041
Oncol Lett. 2018 Feb;15(2):2049-2056
pubmed: 29434904
Sci Rep. 2018 Mar 14;8(1):4482
pubmed: 29540837
Mol Cancer Ther. 2018 Jun;17(6):1187-1195
pubmed: 29563163
Nat Commun. 2018 May 18;9(1):1991
pubmed: 29777137
Biochem Biophys Res Commun. 2018 Jul 2;501(4):1060-1067
pubmed: 29777702
Proteomes. 2018 Jun 21;6(3):null
pubmed: 29933573
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1610-1617
pubmed: 30131250
Int J Cancer. 2019 Feb 15;144(4):755-766
pubmed: 30259975
Mol Ther Methods Clin Dev. 2018 Sep 22;12:1-18
pubmed: 30364598
Biomedicines. 2018 Nov 12;6(4):null
pubmed: 30424477
Int J Nanomedicine. 2018 Oct 24;13:6809-6827
pubmed: 30425490